Oral News and Research

RSS

Novel subdermal implant delivering potent ARV drugs shows promise in stopping HIV

Is the end of HIV near? Findings published this week in Antimicrobial Agents and Chemotherapy report that a novel, subdermal implant delivering potent antiretroviral (ARV) drugs shows extreme promise in stopping the spread of HIV.

29 Apr 2015

Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombosis), or even death.

28 Apr 2015

National survey shows that most women don't know risks or symptoms of stroke

A national survey released today by The Ohio State University Wexner Medical Center shows that most women don't know the risks or symptoms females face when it comes to having a stroke.

28 Apr 2015

Simple device to treat sleep apnea may reduce diabetes risk

Using a simple device for eight hours a night to treat sleep apnea can help people with prediabetes improve their blood sugar levels and may reduce the risk of progressing to diabetes, according to a new study published online in the April 21, 2015, issue of the American Journal of Respiratory and Critical Care Medicine.

28 Apr 2015

New T1D Prevention Initiative launched to identify pathways to prevent type 1 diabetes

As the incidence of type 1 diabetes (T1D) rises worldwide, The Leona M. and Harry B. Helmsley Charitable Trust today announced the launch of an ambitious new T1D Prevention Initiative to investigate the early stages of development of the disease and identify new pathways to prevent it.

28 Apr 2015

MCW announces formation of four-party MOU to provide inadequate access to oral health care in Tanzania

As part of its Oral Health Care Initiative, which has the vision to improve oral health care for all Tanzanians, MCW announced today the formation of an historic four-party Memorandum of Understanding (MOU).

28 Apr 2015

Intarcia Therapeutics announces closing of $225 million synthetic royalty financing

Intarcia Therapeutics, Inc. today announced the closing of a $225 million synthetic royalty financing with an equity conversion option at a $5.5 billion Company valuation. Plans are to use these funds to accelerate the initiation of additional head-to-head comparative and switch studies of ITCA 650 vs. leading oral and injectable type 2 diabetes therapies.

28 Apr 2015

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, today announced the presentation of data demonstrating the promise of its lead clinical candidate, TXA709, in combating antibiotic resistance.

27 Apr 2015

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis.

27 Apr 2015

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

TWi Pharmaceuticals, Inc. today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc. (individually and collectively, "Takeda") to settle and dismiss all outstanding patent litigation related to TWi's generic dexlansoprazole delayed release capsules for oral administration in 30 mg and 60 mg dosage strengths.

27 Apr 2015

New fluid gels delay release of drugs to benefit young children, others

SCIENTISTS at the University of Huddersfield are pioneering the use of a special gel that is ideal for administering medication to young children and others - including the elderly - who have difficulty swallowing pills and capsules. Unlike purely liquid medicines, the gel delays the release of the drug, so that it has maximum effect.

27 Apr 2015

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).

25 Apr 2015

New study shows 'alarming rise' in costs of MS drugs over last 20 years

A new study shows an "alarming rise" over the last 20 years in the costs of drugs used to slow the progression of multiple sclerosis or reduce the frequency of attacks, according to a study led by researchers at Oregon Health & Science University and Oregon State University.

25 Apr 2015

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

A new study led by University of Toronto researcher Dr. David Lam has discovered the trigger behind the most severe forms of cancer pain. Released in top journal Pain this month, the study points to TMPRSS2 as the culprit: a gene that is also responsible for some of the most aggressive forms of androgen-fuelled cancers.

24 Apr 2015

Alternative treatment options for uterine fibroids

A 47-year-old African-American woman has heavy menstrual bleeding and iron-deficiency anemia. She reports the frequent need to urinate during the night and throughout the day. A colonoscopy is negative and an ultrasonography shows a modestly enlarged uterus with three uterine fibroids, noncancerous growths of the uterus.

24 Apr 2015

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Debiopharm International SA, part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far.

23 Apr 2015

HCV-TARGET study: All-oral, direct-acting antiviral therapy for HCV effective in decompensated cirrhosis patients

Interim data presented today at The International Liver Congress 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients with decompensated cirrhosis.

23 Apr 2015

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill).

From Baxter International Inc. 22 Apr 2015

Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

Scientists at Tel Aviv Medical Center, Israel, have found that oral modified citrus pectin (MCP) enhances the anti-cancer and anti-metastatic effects of radiation therapy in the treatment of androgen-independent (AI) aggressive prostate cancer cells.

22 Apr 2015

New treatment shows promise in easing symptoms of Parkinson's disease

To date, a cure for Parkinson's disease remains elusive for the more than 50,000 Americans diagnosed yearly, despite decades of intensive study. But a newly approved treatment that might help ease the symptoms of Parkinson's has shown remarkable promise.

22 Apr 2015

Oral News and Research

Novel subdermal implant delivering potent ARV drugs shows promise in stopping HIV

Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

National survey shows that most women don't know risks or symptoms of stroke

Simple device to treat sleep apnea may reduce diabetes risk

New T1D Prevention Initiative launched to identify pathways to prevent type 1 diabetes

MCW announces formation of four-party MOU to provide inadequate access to oral health care in Tanzania

Intarcia Therapeutics announces closing of $225 million synthetic royalty financing

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

New fluid gels delay release of drugs to benefit young children, others

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

New study shows 'alarming rise' in costs of MS drugs over last 20 years

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

Alternative treatment options for uterine fibroids

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

HCV-TARGET study: All-oral, direct-acting antiviral therapy for HCV effective in decompensated cirrhosis patients

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

New treatment shows promise in easing symptoms of Parkinson's disease

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News